Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioSante+Pharmaceuticals+%28BPAX%29+and+Cell+Genesys+%28CEGE%29+Announce+Final+Exchange+Ratio+for+Merger/4964402.html for the full story.
BioSante Pharmaceuticals says that its planned merger with Cell Genesys will bring in between $20 million and $25 million, which can fund its development program for a gel to treat female sexual dysfunction. LibiGel is now in Phase III trials and...
(Update2) BioSante Pharmaceuticals Inc., the
developer of a gel to treat female sexual dysfunction, aims to
fund clinical trials with cash from its planned acquisition of
Cell Genesys Inc., a developer of cancer vaccines.
BALA CYNWYD, Pa., June 30, 2009 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cell Genesys, Inc. ("Cell Genesys" or the "Company") (Nasdaq:CEGE) related to
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cell+Genesys+%28CEGE%29+Reports+Tender+Offer+Results%2C+Continues+to+Pursue+Strategic+Alternatives/4748442.html for the full story.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Cell Genesys (CEGE):